Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Innovators: COARE Biotechnology

Get in Touch

By Brian Brus

Courtesy of The Journal Record

OKLAHOMA CITY – Dr. Courtney Houchen and his colleagues at Oklahoma City-based COARE Biotechnology are accelerating a new technology to market that shows promise in fighting pancreatic cancer and other solid-tumor cancers, he said.

The challenge of his work is that often bad cells are difficult to diagnose in the pancreas until it’s too late, Houchen said. The pancreas is key in hormone production and digestion. According to National Institutes of Health Cancer Institute projections, 44,000 cases of pancreatic cancer will be found in 2012, while nearly 37,400 related deaths will be reported. So even though the number of pancreatic cancers that are reported annually is smaller than some other cancer types, the value of research on such an insidious problem has significance in many other areas of health treatment, he said.

Dr. Courtney Houchen, COARE Biotechnology“It’s such a deadly, devastating cancer, and there’s no way to detect it earlier,” he said. “Over the years there have been very few drugs that make any impact on pancreatic cancer survival. It’s one of the most dismal of solid tumor cancers. You usually have about six months from the time of diagnosis to death.

“And the pathway to commercialization of technology out of universities is very slow and difficult,” he said. “But it’s the only way that drugs like this can get to market, through technology transfers for financing developing and testing.”

At the University of Oklahoma Cancer Institute, Houchen’s research team discovered a certain cancer protein in stem cells that can be targeted for treatment. He would not discuss many of the details of the treatment compound nor its delivery system.

“We think that it will have a profound effect on how the cancer starts and its strength,” Houchen said.

The company is ready to move from animal testing to humans, he said. COARE is on the verge of the pre-clinical phase, he said.

Financially as well, the company is still at least five years away from market and is currently working with the nonprofit i2E for grant-writing assistance.

“We are desperately looking for funding right now,” he said. “We are looking at government-state funding through small business innovator research grants, and of course we’re open to outside angel investors or corporate investment. We might consider corporate investments and partnerships with biopharmaceutical companies.”

Click here to read the article at the Journal Record website.

 

  • admin
    admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E